5 citations
,
March 2021 in “Hepatitis Monthly” This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.
5 citations
,
June 2019 in “Open Forum Infectious Diseases” This report describes six cases of hair loss in African American women after switching to tenofovir alafenamide, suggesting it as a possible adverse effect in this population.
October 2025 in “Open Repository of the University of Porto (University of Porto)” In this report, the author summarized activities from a six-month internship in community and hospital pharmacy settings, exploring topics like skin microbiome health implications and advancements in antiviral therapy for Hepatitis B and D, highlighting the pharmacist's role in patient care and innovative treatments.
January 2025 in “The Pediatric Infectious Disease Journal” This report details a rare case of late latent syphilis in a 17-year-old male with unusual symptoms like polyarthritis and hair loss, which resolved following antibiotic treatment, highlighting varied syphilis presentations and the importance of STI screening, especially in high-risk groups.